The tumor-bearing host (mean diameter of tumor 5–8 mm) received a lymphodepleting dose of total body irradiation, pmel-1 T cells adoptively transferred intravenously into B16 tumor-bearing mice and gp10025-33 peptide-pulsed dendritic cell vaccination with high-dose IL-2 therapy. This evidence concerns the gene IL2 and neoplasm.